Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer.

Autor: Otero-Estévez O; Department of Biochemistry, Genetics and Immunology, University of Vigo, 36310 Vigo, Spain.; Centro de Investigaciones Biomédicas, Centro Singular de Investigación de Galicia, University of Vigo, 36310 Vigo, Spain., Gallardo-Gomez M; Department of Biochemistry, Genetics and Immunology, University of Vigo, 36310 Vigo, Spain.; Centro de Investigaciones Biomédicas, Centro Singular de Investigación de Galicia, University of Vigo, 36310 Vigo, Spain., Cadena MP; Department of Biochemistry, Genetics and Immunology, University of Vigo, 36310 Vigo, Spain.; Centro de Investigaciones Biomédicas, Centro Singular de Investigación de Galicia, University of Vigo, 36310 Vigo, Spain., Rodríguez-Berrocal FJ; Department of Biochemistry, Genetics and Immunology, University of Vigo, 36310 Vigo, Spain.; Centro de Investigaciones Biomédicas, Centro Singular de Investigación de Galicia, University of Vigo, 36310 Vigo, Spain., Cubiella J; Department of Gastroenterology, Complexo Hospitalario Universitario de Ourense, Instituto de Investigación Biomédica Galicia Sur, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 32005 Ourense, Spain., Ramirez VH; Department of Gastroenterology, Xerencia de Xestión Integrada de Vigo, Instituto de Investigación Biomédica Galicia Sur, 36213 Vigo, Spain., García-Nimo L; Department of Clinical Analysis, Complexo Hospitalario Universitario de Ourense, Instituto de Investigación Biomédica Galicia Sur, 32005 Ourense, Spain., Chiara L; Department of Biochemistry, Genetics and Immunology, University of Vigo, 36310 Vigo, Spain.; Centro de Investigaciones Biomédicas, Centro Singular de Investigación de Galicia, University of Vigo, 36310 Vigo, Spain.
Jazyk: angličtina
Zdroj: Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2020 Jun 28; Vol. 10 (7). Date of Electronic Publication: 2020 Jun 28.
DOI: 10.3390/diagnostics10070437
Abstrakt: Aberrant DNA methylation detected in liquid biopsies is a promising approach for colorectal cancer (CRC) detection, including premalignant advanced adenomas (AA). We evaluated the diagnostic capability of serum NEUROG1 methylation for the detection of AA and CRC. A CpG island in NEUROG1 promoter was assessed by bisulfite pyrosequencing in a case-control cohort to select optimal CpGs. Selected sites were evaluated through a nested methylation-specific qPCR custom assay in a screening cohort of 504 asymptomatic family-risk individuals. Individuals with no colorectal findings and benign pathologies showed low serum NEUROG1 methylation, similar to non-advanced adenomas. Contrarily, individuals bearing AA or CRC (advanced neoplasia-AN), exhibited increased NEUROG1 methylation. Using >1.3518% as NEUROG1 cut-off (90.60% specificity), 33.33% of AN and 32.08% of AA were identified, detecting 50% CRC cases. Nonetheless, the combination of NEUROG1 with fecal immunochemical test (FIT), together with age and gender through a multivariate logistic regression resulted in an AUC = 0.810 for AN, and 0.796 for AA, detecting all cancer cases and 35-47% AA (specificity 98-95%). The combination of NEUROG1 methylation with FIT, age and gender demonstrated a convenient performance for the detection of CRC and AA, providing a valuable tool for CRC screening programs in asymptomatic individuals.
Competing Interests: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje